Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Over the age of 21
- Must have an informant who will be able to provide independent evaluation of
functioning
- English is primary language
- All subjects must have insidious onset, report progression of their symptoms, and meet
current clinical diagnostic criteria for Logopenic Aphasia (LPA) or Posterior Cortical
Atrophy (PCA).
- All subjects with Logopenic Aphasia (LPA) must present with early and dominant
impairments in language
Exclusion Criteria:
- If you have had a stroke or tumor that could explain your symptoms
- Subjects that present with early episodic memory impairment or meet clinical criteria
for mild cognitive impairment will not be recruited into the study
- Subjects that meet specific criteria for another neurodegenerative disorder, including
behavioral variant frontotemporal dementia, semantic dementia, primary progressive
apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy,
will be excluded
- Subjects will be excluded if they have poor vision (20/400)
- Women that are pregnant or post-partum and breast-feeding will be excluded
- Subjects will be excluded from the study if they are unable to undergo the tau-PET
scan due to a prolonged QT interval on ECG, or if they have any of the following
genetic conditions which can increase the chance of cancer: Cowden disease, Lynch
syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome
- Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace
maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may
confound brain imaging studies (e.g. structural abnormalities, including subdural
hematoma or intracranial neoplasm), or if they are medically unstable or are on
medications that might affect brain structure or metabolism,(e.g. chemotherapy)
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Eligibility last updated 7/18/23. Questions regarding updates should be directed to the study team contact.